At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients: a Double Blind Placebo Controlled Randomized Clinical Trial
In Brief
A clinical study evaluating Lactobacillus reuteri, Placebo, and 3 other interventions for Helicobacter Pylori Infection. Completed, enrolled 70 participants across 1 site.
Detailed Summary
Addition of L. reuteri to the standard triple therapy improves H. Pylori treatment outcomes.
Study Details
Timeline
Interventions
Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
All patients will receive omeprazole 20 mg b.i.d for 2 week
amoxicillin 1000 mg b.i.d for 2 weeks
clarithromycin 500mg b.i.d for 2 weeks